I'd bet that it'll exceed tirzepatide by a bit, but they'll hype up the triple agonist action. What's wild is that there's companies doing research for quadrup

I'd bet that it'll exceed tirzepatide by a bit, but they'll hype up the triple agonist action. What's wild is that there's companies doing research for quadruple agonists! Found this[0] company that's looking at one such agonist right now. [0] https://www.biomedind.com/NA-931.html https://www.biomedind.com/NA-931.html